News Chart Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 17:08:52 02/09/2026 +03			5-day change	1st Jan Change
14.24 ^USD	-0.52%		+1.39%	-7.02%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

0b21e1336fea34a0afc85decd.WKoJk2qHqOsTpu75jNCW0HDx72kMDcOCmmqe0eL0nSs.dYdc3A60hYM-lbaBxOLCnl2AhiJPQZnyqlmn6dTZ8Rk5mT-qDbXhuln81g~308914a47fc4d081fa542b3cdafbc3eb